Legal & FDA
    International

    Semaglutide from Mexico or Canada: Is Importing Safe?

    The real risks, legal issues, and better alternatives to buying GLP-1 medications from international pharmacies.

    Last updated: March 31, 2026·14 min read

    Bottom Line

    While semaglutide is cheaper in Mexico and Canada, the risks of importing -- counterfeit products, customs seizure, improper storage, and lack of medical oversight -- generally outweigh the savings. Compounded semaglutide from licensed U.S. pharmacies offers comparable pricing ($200-500/month) without the international risks.

    With brand-name Wegovy costing over $1,300 per month in the United States, it is no surprise that patients are looking across borders for affordable semaglutide. Mexican pharmacies offer Ozempic for a fraction of the U.S. price, and Canadian online pharmacies advertise home delivery. But before you cross the border or place an international order, you need to understand the full picture of risks, legality, and better alternatives.

    Buying Semaglutide in Mexico

    The Appeal

    Mexico does not regulate drug prices the way the U.S. does, and many medications are significantly cheaper. Ozempic in Mexican pharmacies can cost $200-400 USD, compared to $900-1,400 in the U.S. Border towns have thriving pharmacy tourism industries catering to Americans.

    The Risks

    • Counterfeit risk. Mexico has a significant counterfeit medication market. The WHO estimates that up to 10% of medications in developing markets are substandard or falsified. Counterfeit GLP-1 pens are a documented problem.
    • Storage concerns. Temperature control is critical for peptide medications. Semaglutide purchased from a pharmacy that does not maintain proper cold-chain storage may be degraded before you even buy it.
    • Customs seizure. U.S. Customs and Border Protection can seize medications at the border. While personal-use quantities are sometimes allowed, it is discretionary. You may lose your medication and have no refund.
    • No medical oversight. Without an ongoing prescriber relationship, you lack the monitoring, dose adjustments, and safety follow-up that proper GLP-1 treatment requires.
    • Different formulations. Medications sold internationally may have different formulations, concentrations, or inactive ingredients than U.S. versions.

    Buying Semaglutide from Canada

    The Appeal

    Canadian pharmacies generally maintain higher quality standards than Mexican pharmacies, and Health Canada's regulatory framework is comparable to the FDA's. Online Canadian pharmacies offer the convenience of home delivery.

    The Risks

    • Many "Canadian" pharmacies are not actually Canadian. The FDA has found that numerous websites claiming to be Canadian pharmacies are actually based in other countries with lower quality standards.
    • Shipping logistics. Temperature-controlled shipping across borders is challenging. Medications may be exposed to heat or cold during transit.
    • Legal grey area. While the FDA has generally exercised discretion for personal-use imports, it is not guaranteed. The legal landscape could change at any time.
    • Supply limitations. Canada has experienced its own semaglutide shortages. Health Canada has restricted exports to protect domestic supply.
    • Limited recourse. If you receive a defective product, your legal options for recourse with an international seller are limited.

    Better Alternatives Available in the U.S.

    Before looking internationally, consider these domestic options that offer comparable savings without the risks:

    Safer, Affordable U.S. Options

    • Compounded semaglutide ($200-500/month): From licensed U.S. pharmacies with proper quality controls, prescription requirement, and medical oversight.
    • Telehealth programs ($199-599/month): All-inclusive programs including medication, consultations, and shipping.
    • Manufacturer savings programs: Wegovy and Zepbound savings cards can reduce costs for commercially insured patients.
    • Zepbound cash-pay ($550/month): Eli Lilly's direct cash-pay program for tirzepatide.
    • HSA/FSA accounts: Tax-advantaged savings for medical expenses including GLP-1 medications.
    • Patient assistance programs: Free medication for qualifying low-income patients.

    If You Do Decide to Import: Harm Reduction

    While we recommend domestic alternatives, if you have already decided to import medication, these steps reduce (but do not eliminate) risk:

    • Purchase only from pharmacies verified by CIPA (Canadian International Pharmacy Association) for Canadian sources
    • For Mexico, use only major chain pharmacies (Farmacias del Ahorro, Farmacia Guadalajara) in reputable locations, not border-town tourist pharmacies
    • Verify the medication visually upon receipt: clear, colorless, proper packaging, correct lot numbers
    • Use a medication travel cooler for transport
    • Maintain a relationship with a U.S. healthcare provider for medical monitoring
    • Keep all receipts and documentation

    Key Takeaways

    • Semaglutide is cheaper in Mexico ($200-400) and Canada ($300-600) but comes with significant risks
    • Counterfeit medications, customs seizure, and improper storage are real concerns
    • U.S. compounded semaglutide offers comparable pricing ($200-500/month) from licensed pharmacies
    • Telehealth programs provide all-inclusive GLP-1 access without international risks
    • The savings from importing rarely justify the safety and legal risks
    • If you do import, verify sources carefully and maintain medical oversight

    Medical Disclaimer: This article is for educational purposes only and does not constitute medical or legal advice. The legality of importing medications varies by situation. Consult with a healthcare provider for safe GLP-1 access options.

    Affordable GLP-1 Access Without the Risk

    Get quality-assured semaglutide or tirzepatide from verified U.S. pharmacies with medical oversight included.

    Get Started Today

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the published clinical evidence show for compounded semaglutide?

    Peer-reviewed evidence: Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021). Trimi offers compounded semaglutide starting at $99/month on the annual plan, dispensed by 503A community sterile compounding pharmacies (VialsRx — Texas pharmacy license #35264 — and GreenwichRx). Results vary by individual; eligibility is determined by a licensed clinician.

    Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. — STEP 1, NEJM 2021
    Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. — STEP 4, JAMA 2021
    Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. — SELECT, NEJM 2023

    Key Takeaways

    • Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021)
    • Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. (Source: STEP 4, JAMA 2021)
    • Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. (Source: SELECT, NEJM 2023)
    • Semaglutide is the active pharmaceutical ingredient; it is FDA-approved in the corresponding brand finished products (Wegovy and Ozempic). Trimi's compounded preparation of the same active ingredient is prepared per individual prescription by 503A community sterile compounding pharmacies and is not itself FDA-approved as a drug.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: June 2, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    I'm on my 4th week. No side effects. 5 lb loss which seems slow to me. Food noise is much better. We shall see!

    Outcome: 5 lbs lost in 4 weeks; no side effects; food noise reduced

    Lynn SchweitzerFacebook
    21 lbs down in 6 weeks! So happy I started with you guys!

    Outcome: 21 lbs lost in 6 weeks

    Robyn Lynn CurtisFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2032183
    2. Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA.Read StudyDOI: 10.1001/jama.2021.3224
    3. Garvey WT, Batterham RL, Bhatta M, et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine.Read StudyDOI: 10.1038/s41591-022-02026-4
    4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2307563
    5. Marso SP, Bain SC, Consoli A, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa1607141
    6. Perkovic V, Tuttle KR, Rossing P, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2403347

    Was this article helpful?

    Keep Reading

    Clinician-reviewed Trimi guide to semaglutide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded semaglutide option compares to brand alternatives.

    Clinician-reviewed Trimi guide to semaglutide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded semaglutide option compares to brand alternatives.

    Clinician-reviewed Trimi guide to semaglutide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded semaglutide option compares to brand alternatives.

    Clinician-reviewed Trimi guide to semaglutide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded semaglutide option compares to brand alternatives.

    Start your GLP-1 journey — from $99/mo

    Get Started